NR3C1 and congenital adrenal hyperplasia: In the early stages of pregnancy, sGC may be used in conjunction with other drugs as part of immunomodulatory treatments to improve the outcomes of in vitro fertilization7 or given in early gestation to prevent virilization in female foetuses, where there is a risk of congenital adrenal hyperplasia (CAH).8, 9, 10 The effects of sGC, such as Dexamethasone (DEX), are mediated via activation of the glucocorticoid receptor (GR).